Byrne Asset Management’s Amplify Treatments, Testing and Advancements ETF GERM Stock Holding History

Byrne Asset Management’s Portfolio GERM Stock Details GERM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-350	Closed	-$6K	–	589
2023 Q3	$6K	Hold	350	–	–	0.01%	389
2023 Q2	$7K	Hold	350	–	–	﹤0.01%	443
2023 Q1	$7K	Hold	350	–	–	0.01%	433
2022 Q4	$7.83K	Hold	350	–	–	0.01%	400
2022 Q3	$7K	Hold	350	–	–	0.01%	384
2022 Q2	$8K	Hold	350	–	–	0.01%	385
2022 Q1	$10K	Hold	350	–	–	0.01%	388
2021 Q4	$12K	Buy	+350	New	+$13.1K	0.01%	366

Other funds holding GERM

GBWM

Granite Bay Wealth Management Portsmouth, New Hampshire $470M AUM 15.4% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

CHC

City Holding Co Charleston, West Virginia $884M AUM 27.52% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Byrne Asset Management's GERM Position: Q4 2023 in Review

Byrne Asset Management sold out of Amplify Treatments, Testing and Advancements ETF (GERM) in Q4 2023, closing a stake of 350 shares — an estimated $6K sold.

Byrne Asset Management first reported a position in GERM in Q4 2021 and held it in 8 quarters. The position peaked at $12K in Q4 2021. 14 funds tracked by Wall St. Rank hold GERM as of Q4 2023.

Byrne Asset Management reported no remaining Amplify Treatments, Testing and Advancements ETF position as of Q4 2023 after selling out during the quarter.
Byrne Asset Management sold 350 Amplify Treatments, Testing and Advancements ETF shares in Q4 2023, an estimated $6K.
Byrne Asset Management first reported a position in Amplify Treatments, Testing and Advancements ETF in Q4 2021 and held it in 8 quarters.
Byrne Asset Management's Amplify Treatments, Testing and Advancements ETF position peaked at $12K in Q4 2021.
14 funds tracked by Wall St. Rank held Amplify Treatments, Testing and Advancements ETF as of Q4 2023.

Based on Byrne Asset Management's 13F filing for Q4 2023, filed 29 Jan 2024.